New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 25, 2014
16:17 EDTAMGN, WDCWestern Digital CFO Leyden to retire, Olivier Leonetti to succeed
Western Digital (WDC) announced that CFO Tim Leyden is retiring. He is being succeeded by Olivier Leonetti, who has served as vice president, finance at Amgen (AMGN) from 2011. Leyden will remain with the company through January 2015 in a transition role and advisory capacity to president and chief executive officer Steve Milligan and to Leonetti for an interim period to ensure a smooth transition. The changes are effective as of September 8.
News For WDC;AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 31, 2015
19:23 EDTAMGNAmgen initiated with a Market Perform at Raymond James
12:09 EDTWDCSanDisk jumps as buyout rumors resurface
Subscribe for More Information
10:53 EDTWDCSanDisk off lows amid takeover speculation
Subscribe for More Information
06:35 EDTAMGNAlnylam price target raised to $184 from $180 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Alnylam Pharmaceuticals (ALNY) to $184 saying the company over the weekend reported positive Phase I data on ALN-PCS showing LDL-cholesterol lowering comparable to Amgen (AMGN) and Sanofi/Regeneron's (REGN) anti-PCSK9 antibodies, but with only quarterly or potentially every 6-month injections. Tenthoff recommends using the recent pullback in shares of Alnylam as a buying opportunity and keeps an Overweight rating on the name.
August 30, 2015
15:50 EDTAMGNAlnylam, The Medicines Co. say ALN-PCSsc reduces LDL cholesterol as much as 83%
Subscribe for More Information
August 28, 2015
13:53 EDTAMGNAnthem has not made coverage decision about Amgen's Repatha, Bloomberg reports
Bloomberg cites an emailed statement from Anthem (ANTM) regarding Amgen's (AMGN) Repatha injection, which was approved last night by the FDA as an option for some patients who are unable to get their low-density lipoprotein cholesterol under control with current treatment options.
08:01 EDTAMGNAmgen pricing for Repatha competitive with Praluent, says Piper Jaffray
After the FDA announced last night that it has approved Amgen's (AMGN) Repatha injection, Piper Jaffray analyst Joshua Schimmer said that the drug's indications seem "generally in line" with those for Praluent from Regeneron (REGN) and Sanofi (SNY). Amgen disclosed an annual WAC of $14,100 for Repatha, which the analyst notes is about $500 per year below Praluent, but Schimmer said that the actual recognized price for each will ultimately be determined by discounting. Schimmer also noted that Amgen said it is working with payers and other purchasers on "innovative pricing programs," though he is uncertain if that means the company is working on a kind of "pay per performance" scheme. The analyst, who believes the market will prove large enough for both treatments, keeps a $200 price target and Overweight rating on Amgen shares.
August 27, 2015
19:14 EDTAMGNExpress Scripts to cover both Repatha, Praluent for now, Bloomberg says
Subscribe for More Information
18:52 EDTAMGNOn The Fly: After Hours Movers
Subscribe for More Information
17:58 EDTAMGNEsperion up 1.9% after FDA approves Amgen cholesterol drug Repatha
Subscribe for More Information
17:55 EDTAMGNAmgen confirms FDA approval of Repatha cholesterol-lowering medication
Subscribe for More Information
17:24 EDTAMGNFDA approves Repatha
The U.S. Food and Drug Administration approved Repatha injection for some patients who are unable to get their low-density lipoprotein cholesterol under control with current treatment options. Repatha is marketed by Amgen Inc., of Thousand Oaks, Calif. Reference Link
10:00 EDTWDCOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:06 EDTAMGNFDA PDUFA Date for Amgen's Repatha is August 27, 2015
07:09 EDTWDCWestern Digital initiated with an Outperform at Wells Fargo
Subscribe for More Information
August 26, 2015
06:02 EDTAMGNAmgen implied volatility of 41 at upper end of index
August 25, 2015
09:16 EDTAMGNAmgen to present Repatha data analysis at ESC Congress 2015
Subscribe for More Information
09:02 EDTAMGNAmgen submits NDA for hyperparathyroidism treatment
Subscribe for More Information
August 24, 2015
13:36 EDTAMGNBiotech correction presents some opportunities, says RBC Capital
RBC Capital analyst Michael Yee said he won't try to pick the short-term bottom in biotech, but contends that any macro weakness in China shouldn't have any major impact to financials or fundamentals for the sector given their minimal exposure there. If the market continues to be volatile, Yee recommends a focus on names with defensive characteristics, such as higher margins and free cash flow yield, naming Amgen (AMGN), Celgene (CELG) and Gilead (GILD) as some examples. The analyst adds that he likes Vertex (VRTX) on the pullback for "more aggressive" growth investors. Yee has Outperform ratings on all of the stocks mentioned above.
August 21, 2015
09:40 EDTWDCWestern Digital Q3 TAM tracking ahead of guidance, says Cleveland Research
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use